Targets › IGHMBP2
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Mar 2027.
5' to 3' helicase that unwinds both RNA and DNA duplexes in an ATP-dependent reaction (Probable). Specific to 5'-phosphorylated single-stranded guanine-rich sequences. (UniProt, P38935)
Open in Phaseline: the race on IGHMBP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals | VCA-894A antisense oligonucleotide targeting IGHMBP2 | IGHMBP2 | Phase 1 | Charcot Marie Tooth Disease (CMT) | Mar 2027 |
Charcot Marie Tooth Disease (CMT) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.